Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2025)

Historic Common Equity for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to $29.7 million.

  • Neuphoria Therapeutics' Common Equity rose 11603.75% to $29.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.7 million, marking a year-over-year increase of 11603.75%. This contributed to the annual value of $19.0 million for FY2025, which is N/A changed from last year.
  • Per Neuphoria Therapeutics' latest filing, its Common Equity stood at $29.7 million for Q4 2025, which was up 11603.75% from $12.5 million recorded in Q3 2025.
  • Neuphoria Therapeutics' 5-year Common Equity high stood at $43.9 million for Q4 2021, and its period low was $12.5 million during Q3 2025.
  • In the last 5 years, Neuphoria Therapeutics' Common Equity had a median value of $22.2 million in 2023 and averaged $25.0 million.
  • In the last 5 years, Neuphoria Therapeutics' Common Equity crashed by 4565.24% in 2023 and then skyrocketed by 11603.75% in 2025.
  • Quarter analysis of 5 years shows Neuphoria Therapeutics' Common Equity stood at $43.9 million in 2021, then fell by 7.17% to $40.8 million in 2022, then tumbled by 45.65% to $22.2 million in 2023, then tumbled by 37.95% to $13.7 million in 2024, then skyrocketed by 116.04% to $29.7 million in 2025.
  • Its Common Equity was $29.7 million in Q4 2025, compared to $12.5 million in Q3 2025 and $19.0 million in Q2 2025.